New combo therapy aims to stop brain tumors from growing in lung cancer patients
NCT ID NCT07443397
First seen Mar 05, 2026 · Last updated May 16, 2026 · Updated 11 times
Summary
This study tests whether adding the targeted drug anlotinib to whole-brain radiation helps control brain tumors better than radiation alone in people with small cell lung cancer that has spread to the brain. About 134 participants will be randomly assigned to one of two groups. The goal is to see if the combination delays tumor growth or death, and to find which patients benefit most.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for WHOLE-BRAIN RADIOTHERAPY are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
National Cancer Center/Cancer Hospital, Chinese Academy of Medical Science and Peking Union Medical College
RECRUITINGBeijing, Beijing Municipality, 100004, China
Contact Phone: •••-•••-••••
Conditions
Explore the condition pages connected to this study.